Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat to Augment Response to 177Lu-PSMA-617 in PSMA-Low mCRPC
NCT06145633Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in prostate cancer (PCa), sponsored by Fred Hutchinson Cancer Center. Started Sep 2024; status: recruiting.
02
Drugs
vorinostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06145633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145633.